Compression Works Receives Additional 510(k) Clearance from the FDA for the AAJT-S Life-Saving Junctional Tourniquet

Compression Works, Inc. manufacturer of the Abdominal Aortic and Junctional Tourniquet-Stabilized (AAJT-S) device, announces a new 510(k) clearance from the FDA.  This is the third 510(k) clearance granted by the U.S. Food and Drug Administration (FDA) for the AAJT-S technology.

The AAJT-S junctional tourniquet is designed to control non-compressible hemorrhages in the junctional areas of the anatomy, on the abdomen and for pelvic fracture stabilization. “We are thrilled at the ever-expanding indication range for the AAJT-S and are happy to announce this new clearance by the FDA,” said President and CEO of Compression Works Scott Dodson. “Pelvic fractures that result from automobile accidents, crushing injuries and falls represent a serious health issue and even mortality for accident victims due to their potential to rupture the underlying blood vessels in this area,” said Dodson.

“The U.S. Department of Transportation reports 150,000 pelvic fractures per year. Of those that die, up to 40% are as a result of an underlying hemorrhage due to the disruption in the pelvis. The AAJT-S device can stabilize the broken structure so the accident victim can be safely transported to definitive care for an awaiting surgical team.  If there is suspected pelvic bleeding, the AAJT-S can also be used to stop the blood flow to the damaged area,” stated Chief Medical Officer John Croushorn, MD.

The AAJT-S from Compression Works has five distinct uses. The device can be used in the axilla and groin to stop junctional hemorrhage, and is the only junctional tourniquet cleared for use on the abdomen for pelvic bleeding and bilateral lower leg injuries. The AAJT-S can also be used as an adjunct to Zone 3 REBOA as proven in multiple peer-reviewed clinical studies.  With the additional FDA clearance for pelvic fractures, the AAJT-S offers more multi-use capabilities for critical areas of the body to help save lives.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version